Advertisement

Endocrine

pp 1–7 | Cite as

Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response

  • Jonghwa Ahn
  • Eyun Song
  • Won Gu Kim
  • Tae Yong Kim
  • Won Bae Kim
  • Young Kee Shong
  • Min Ji JeonEmail author
Original Article
  • 32 Downloads

Abstract

Purpose

The aim of this study was to evaluate the long-term clinical outcomes of papillary thyroid carcinoma (PTC) patients exhibiting biochemical incomplete response (BIR) to initial therapy.

Methods

We evaluated 102 patients with PTC showing a BIR during the first 12–24 months after total thyroidectomy and radioactive iodine therapy. Patients were divided into three groups according to changes in stimulated thyroglobulin (Tg) and anti-Tg antibody (TgAb) levels: the increasing TgAb group (n = 19, 18.6%), the decreasing Tg group (n = 58, 56.9%), and the increasing Tg group (n = 25, 24.5%).

Results

With a median follow-up of 12 years, 43 (42%) patients had structural persistent disease as follows: 36 (84%) at regional sites and 7 (16%) at distant sites. The rate of structural persistent disease was significantly different between groups, with 21%, 41%, and 60% in the increasing TgAb, decreasing Tg, and increasing Tg groups, respectively (P = 0.012). Among patients without structural persistent disease, only 19 (18.6%) showed no evidence of disease and 40 (39.2%) were of a biochemical persistent status at the time of final follow-up. Increasing Tg after initial therapy was a significant risk factor for structural persistent disease in patients with BIR (HR, 4.16; 95% confidence interval (CI): 1.3812.54, P = 0.011).

Conclusions

PTC patients with BIR showed a high rate of structural persistent disease and Tg change after initial therapy is the most important prognostic factor for determining clinical outcomes of these patients.

Keywords

Papillary thyroid carcinoma Prognosis Dynamic risk stratification Biochemical incomplete response 

Notes

Acknowledgements

This study was supported by the National Research Foundation (NRF) of Korea Research Grant (NRF-2017R1D1A1B03028231).

Author contributions

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by J.A., E.S, and M.J.J. The first draft of the manuscript was written by J.A. and all authors commented on the previous versions of the manuscript. All the authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

The study protocol was approved by the Institutional Review Board (IRB) of the Asan Medical Center. The IRB of the Asan Medical Center confirms that patient consent was not required for this retrospective study.

References

  1. 1.
    C. Durante, T. Montesano, M. Torlontano, M. Attard, F. Monzani, S. Tumino, G. Costante, D. Meringolo, R. Bruno, F. Trulli, M. Massa, A. Maniglia, R. D’Apollo, L. Giacomelli, G. Ronga, S. Filetti; PTC Study Group, Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J. Clin. Endocrinol. Metab. 98, 636–642 (2013)CrossRefGoogle Scholar
  2. 2.
    L. Lamartina, T. Montesano, F. Trulli, M. Attard, M. Torlontano, R. Bruno, D. Meringolo, F. Monzani, S. Tumino, G. Ronga, M. Maranghi, M. Biffoni, S. Filetti, C. Durante, Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. Endocrine 54, 467–475 (2016)CrossRefGoogle Scholar
  3. 3.
    B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)CrossRefGoogle Scholar
  4. 4.
    M. B. Amin, S. Edge, F. Greene, D. R. Byrd, R. K. Brookland, M. K. Washington, J. E. Gershenwald, C. C. Compton, K. R. Hess, D. C. Sullivan, J. M. Jessup, J. D. Brierley, L. E. Gaspar, R. L. Schilsky, C. M. Balch, D. P. Winchester, E. A. Asare, M. Madera, D. M. Gress, L. R. Meyer, AJCC Cancer Staging Manual, 8th edn. (Springer, New York, 2017)Google Scholar
  5. 5.
    R.M. Tuttle, H. Tala, J. Shah, R. Leboeuf, R. Ghossein, M. Gonen, M. Brokhin, G. Omry, J.A. Fagin, A. Shaha, Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20, 1341–1349 (2010)CrossRefGoogle Scholar
  6. 6.
    R. M. Tuttle, A. S. Alzahrani, Risk stratification in differentiated thyroid cancer: from detection to final follow-up. J. Clin. Endocrinol. Metab. 104, 4087–4100 (2019).  https://doi.org/10.1210/jc.2019-00177 CrossRefGoogle Scholar
  7. 7.
    M.G. Castagna, F. Maino, C. Cipri, V. Belardini, A. Theodoropoulou, G. Cevenini, F. Pacini, Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur. J. Endocrinol. 165, 441–446 (2011)CrossRefGoogle Scholar
  8. 8.
    F. Vaisman, D. Momesso, D.A. Bulzico, C.H. Pessoa, F. Dias, R. Corbo, M. Vaisman, R.M. Tuttle, Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin. Endocrinol. (Oxf.) 77, 132–138 (2012)CrossRefGoogle Scholar
  9. 9.
    M.J. Jeon, M. Kim, S. Park, H.S. Oh, T.Y. Kim, W.B. Kim, Y.K. Shong, W.G. Kim, A follow-up strategy for patients with an excellent response to initial therapy for differentiated thyroid carcinoma: less is better. Thyroid 28, 187–192 (2018)CrossRefGoogle Scholar
  10. 10.
    H.S. Oh, J.H. Ahn, E. Song, J.M. Han, W.G. Kim, T.Y. Kim, W.B. Kim, Y.K. Shong, M.J. Jeon, Individualized follow-up strategy for patients with an indeterminate response to initial therapy for papillary thyroid carcinoma. Thyroid 29, 209–215 (2019)CrossRefGoogle Scholar
  11. 11.
    P.W. Rosario, M. Carvalho, G.F. Mourao, M.R. Calsolari, Comparison of antithyroglobulin antibody concentrations before and after ablation with 131I as a predictor of structural disease in differentiated thyroid carcinoma patients with undetectable basal thyroglobulin and negative neck ultrasonography. Thyroid 26, 525–531 (2016)CrossRefGoogle Scholar
  12. 12.
    M.J. Jeon, W.G. Kim, W.R. Park, J.M. Han, T.Y. Kim, D.E. Song, K.W. Chung, J.S. Ryu, S.J. Hong, Y.K. Shong, W.B. Kim, Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 170, 23–30 (2014)CrossRefGoogle Scholar
  13. 13.
    R.C. Smallridge, N. Diehl, V. Bernet, Practice trends in patients with persistent detectable thyroglobulin and negative diagnostic radioiodine whole body scans: a survey of American Thyroid Association members. Thyroid 24, 1501–1507 (2014)CrossRefGoogle Scholar
  14. 14.
    M. Brassard, I. Borget, A. Edet-Sanson, A.L. Giraudet, O. Mundler, M. Toubeau, F. Bonichon, F. Borson-Chazot, L. Leenhardt, C. Schvartz, C. Dejax, I. Brenot-Rossi, M.E. Toubert, M. Torlontano, E. Benhamou, M. Schlumberger; Thyrdiag Working Group, Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J. Clin. Endocrinol. Metab. 96, 1352–1359 (2011)CrossRefGoogle Scholar
  15. 15.
    F. Pitoia, E. Abelleira, H. Tala, F. Bueno, C. Urciuoli, G. Cross, Biochemical persistence in thyroid cancer: is there anything to worry about? Endocrine 46, 532–537 (2014)CrossRefGoogle Scholar
  16. 16.
    R.M. Tuttle, Optimal management of a biochemical incomplete response to therapy in differentiated thyroid cancer: aggressive treatment or cautious observation? Endocrine 46, 363–364 (2014)CrossRefGoogle Scholar
  17. 17.
    N.K. Zern, R. Clifton-Bligh, A.J. Gill, A. Aniss, S. Sidhu, L. Delbridge, D. Learoyd, B. Robinson, M. Sywak, Disease progression in papillary thyroid cancer with biochemical incomplete response to initial therapy. Ann. Surg. Oncol. 24, 2611–2616 (2017)CrossRefGoogle Scholar
  18. 18.
    C.A. Spencer, M. Takeuchi, M. Kazarosyan, C.C. Wang, R.B. Guttler, P.A. Singer, S. Fatemi, J.S. LoPresti, J.T. Nicoloff, Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 83, 1121–1127 (1998)PubMedGoogle Scholar
  19. 19.
    J.K. Chung, Y.J. Park, T.Y. Kim, Y. So, S.K. Kim, D.J. Park, D.S. Lee, M.C. Lee, B.Y. Cho, Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin. Endocrinol. (Oxf.) 57, 215–221 (2002)CrossRefGoogle Scholar
  20. 20.
    S. Park, W.G. Kim, E. Song, H.S. Oh, M. Kim, H. Kwon, M.J. Jeon, T.Y. Kim, Y.K. Shong, W.B. Kim, Dynamic risk stratification for predicting recurrence in patients with differentiated thyroid cancer treated without radioactive iodine remnant ablation therapy. Thyroid 27, 524–530 (2017)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Jonghwa Ahn
    • 1
  • Eyun Song
    • 1
  • Won Gu Kim
    • 1
  • Tae Yong Kim
    • 1
  • Won Bae Kim
    • 1
  • Young Kee Shong
    • 1
  • Min Ji Jeon
    • 1
    Email author
  1. 1.Division of Endocrinology & Metabolism, Department of Internal Medicine, Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guRepublic of Korea

Personalised recommendations